The Broad Institute, Boston Children’s Hospital, and Jackson Laboratory launched a new Center for Therapeutic Genetics aimed at accelerating gene therapy development for rare diseases through shared protocols and a more standardized clinical pathway. The effort is supported by a $34.5 million ARPA-H grant and is designed to make gene editing approaches more scalable in deployment, modeled more like procedures such as surgery than bespoke one-off programs. The first target indications include rare pediatric epilepsies tied to ATP1A3 and SCN1A mutations, with plans to expand to other disease areas over time. Leaders said the center will focus on selecting programs with a cadence of successes to create evidence quickly despite regulatory challenges for small patient populations. For the field, the center’s emphasis on shared methods and data-sharing is a concrete attempt to reduce fragmentation in how rare-disease gene therapies are built and advanced.